Arcutis Biotherapeutics Inc ((ARQT)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arcutis Biotherapeutics Inc. recently completed a Phase 3 clinical study titled ‘A Randomized Trial Employing Topical Roflumilast Foam to Treat Scalp Psoriasis (ARRECTOR)’. The study aimed to evaluate the safety and efficacy of roflumilast foam 0.3% in treating plaque psoriasis on the scalp and body. This research is significant as it explores a potential new treatment option for psoriasis, a condition affecting millions worldwide.
The study tested a topical intervention, roflumilast foam 0.3%, against a placebo vehicle foam. Roflumilast is intended to reduce the symptoms of psoriasis, such as itching and scaling, by applying it once daily for eight weeks.
The study was interventional, with participants randomly assigned to either the roflumilast or placebo group. It was a double-blind study, meaning neither the participants nor the researchers knew who received the active treatment. The primary goal was to assess treatment effectiveness.
The study began on August 24, 2021, and was completed with results submitted on May 28, 2025. The last update was on July 16, 2025. These dates are crucial as they mark the progress and completion of the study, providing a timeline for investors to track the development of the treatment.
The completion of this study could positively impact Arcutis Biotherapeutics’ stock performance, as successful results may lead to new product offerings in the psoriasis treatment market. This could enhance investor sentiment, especially if the treatment proves more effective than existing options. Competitors in the dermatology space will likely monitor these developments closely.
The study is completed, and further details are available on the ClinicalTrials portal.